With the European Commission's (EC) approval of Tyruko, Europe receives its first natalizumab biosimilar and first biosimilar to treat multiple sclerosis (MS), while Coherus Biosciences received a complete response letter (CRL) for its biosimilar for Neulasta Onpro.
The European Commission (EC) approved Tyruko, the first natalizumab biosimilar and first biosimilar to treat multiple sclerosis (MS) approved in Europe, and Coherus Biosciences received a complete response letter (CRL) from the FDA regarding its biosimilar competitor for Neulasta Onpro.
EC Approval of Tyruko
The EC granted marketing authorization to Tyruko, a natalizumab biosimilar referencing Tysabri. The product was developed by Polpharma Biologics, a Poland-based pureplay biosimilar manufacturer, and will be marketed by Sandoz as part of a global commercialization agreement.
Tyruko was approved as a single disease-modifying therapy in adults with highly active relapsing-remitting MS (RRMS), the same indication as approved by the EC for the reference medicine. The European approval comes 2 months after the European Medicines Agency’s Committee for Medicinal Products for Human Use gave a positive opinion on Tyruko and one month after the FDA approved the drug for the US market.
“This biosimilar is extremely big news,” said Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, in an interview with The Center for Biosimilars® regarding the US approval. "I know there's so much focus on the adalimumab biosimilars right now but introducing a brand new therapeutic area, with neurology and a biosimilar, is very, very exciting."
The EC based its approval on the analytical, preclinical, and clinical data collected from a phase 1 pharmacokinetic and pharmacodynamic study and the phase 3 ANTELOPE study, which confirmed the comparable safety, efficacy, and immunogenicity profiles of Tyruko and the originator in patients with RRMS.
“We are delighted that the European approval of Tyruko comes hot on the heels of approval in the US, meaning that millions of people living with multiple sclerosis around the world may soon have the option of a more affordable treatment for their disease….,” commented Michael Soldan, CEO, Polpharma Biologics Group. "We’re building on this extensive scientific and manufacturing expertise to further advance our pipeline of other high potential biosimilar targets."
Natalizumab biosimilars can help ease the burden of high costs related to MS treatment, which is estimated to cost health systems as much as €37,000 to €57,000 ($38,881-$59,899) per patient per year.
CRL for Neulasta Onpro Biosimilar
Coherus Biosciences received a CRL for its biosimilar of Neulasta Onpro, a biobetter of the original Neulasta (pegfilgrastim) formulation that allows for an on-body injector device. Pegfilgrastim products are used to lower a patient’s risk of developing febrile neutropenia, a potentially life-threatening condition that can result after receiving chemotherapy.
The CRL will delay the anticipated US approval of the on-body product. However, it does not impact the sales or regulatory status of Udenyca (pegfilgrastim-cbqv), Coherus’ original pegfilgrastim biosimilar. Udenyca was approved in November 2018 and launched on the US market in January 2019. It is 1 of 6 pegfilgrastim biosimilars approved for the US market.
The letter comes after the FDA approved the autoinjector version of Udenyca in March 2023. The autoinjector device allows for patients to be administered pegfilgrastim the day after receiving chemotherapy, decreasing the risk of patients developing febrile neutropenia. The Udenyca autoinjector is triggered by push-on-skin activation, allowing for reliable and immediate delivery of a full pegfilgrastim dose.
Coherus assured that the FDA did not raise any issues with the on-body product’s safety or efficacy, saying that the CRL was issued because of an ongoing review at a third-party manufacturing site.
Switching to Rituximab Biosimilars Is Safe, Effective for Patients With Oncohematological Diseases
December 5th 2024Patients with oncohematological diseases switching to rituximab biosimilars experienced similar safety and efficacy, highlighting biosimilars' potential for cost-effective treatment across various medical conditions.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Omalizumab Biosimilar Shows Equivalent Efficacy as Multiple Sclerosis Treatment
November 26th 2024The phase 3 trial (NCT04966338) found that a biosimilar ocrelizumab candidate (Xacrel) was equivalent to Ocrevus in reducing the annualized relapse rate and showed comparable safety and efficacy in treating relapsing multiple sclerosis over 96 weeks.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.